BioSpace News Archive

Aveanna Healthcare Holdings Inc. announced financial results for the three-month period and fiscal year ended December 30, 2023.

InfuSystem Holdings, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023, and provided a business update.

Pluri Inc. announced that its CDMO division has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.

Satellos Bioscience Inc. announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences.

Faron Pharmaceuticals Ltd. announces it will host a virtual BEXMAB update event on Tuesday, March 19 at 11.00 EET/9am GMT, following the most recent data cut-off and scheduled analysis.

Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million.

Sibylla Biotech announced a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System disorders.

BIOLASE, Inc. announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update.